Increase in geriatric population globally and rise in prevalence of prostate cancer due to hectic lifestyle, ethnicity, unhealthy diet, and lack of awareness are expected to fuel the market growth.
Portland, OR -- (SBWIRE) -- 08/24/2017 -- Prostate Cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence.
Early buyers will receive 20% customization on this report.
Increase in geriatric population globally and rise in prevalence of prostate cancer due to hectic lifestyle, ethnicity, unhealthy diet, and lack of awareness are expected to fuel the market growth. According to the National Cancer Institute, in the U.S., prostate cancer is estimated to cause about 26,730 deaths in 2017. In addition, R&D activities in the field of prostate cancer drugs and emerging economies in developing countries are expected to present new opportunities during the forecast period.
Request for Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/2653
However, stringent government regulations, high cost of prostate cancer medicines and low awareness of prostate cancer restrict the growth.
The prostate cancer medicine market is segmented on the basis of drug type and geography. Based on drug type, it is divided into hormonal therapy drugs, chemotherapy drugs, immunotherapy drugs, and target therapy drugs. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.